• metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) 5
• mNSCLC - L2 - adenocarcinoma cell
• mNSCLC - L2 - all population 5
• mNSCLC - L2 - EGFR high
• mNSCLC - L2 - EGFR mutant 1
• mNSCLC - L2 - EGFR wild type
• mNSCLC - L2 - KRAS mutant
• mNSCLC - L2 - KRAS wild type
• mNSCLC - L2 - PDL1 negative 1
• mNSCLC - L2 - PDL1 positive 7
• non squamous cell - mNSCLC - L2
• non squamous - mNSCLC - L2 - all population 1
• non squamous - mNSCLC - L2 - EGFR mutant
• non squamous - mNSCLC - L2 - PDL1 positive
• non squamous - mNSCLC - L2 - wild type (WT)
• squamous cell - mNSCLC - L2
• squamous - mNSCLC - L2 - all population 1
• squamous - mNSCLC - L2 - PDL1 positive

 

• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus BSC
• HER inhibitor
• EGFR inhibitor
• erlotinib based treatment
• tivantinib plus erlotinib

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs HER inhibitor
• vs EGFR inhibitor
• vs erlotinib based treatment
• vs Erlotinib plus BSC

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)